NDAORALCAPSULEPriority Review
Approved
May 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
Priority Review
PROGLYCEM (diazoxide) by Teva is clinical pharmacology diazoxide produces a dose-related increase in blood glucose, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect. First approved in 1976.
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROGLYCEM (diazoxide) is an oral small-molecule hyperglycemic agent approved in 1976 that increases blood glucose by inhibiting insulin release from the pancreas and reducing sodium/water excretion. It is used to manage hypoglycemia in patients with inoperable pancreatic tumors or other conditions where insulin secretion is excessive. The drug works through direct pancreatic beta-cell inhibition and extrapancreatic mechanisms.
$0.206MPart D
LOE ApproachingMinimal commercial activity with only $206K Part D spending and 72 claims in 2023 indicates a niche, declining product with a small commercial footprint.
Mechanism of Action
CLINICAL PHARMACOLOGY Diazoxide produces a dose-related increase in blood glucose, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect. The hyperglycemic effect of diazoxide begins within an hour and generally lasts no more than eight hours in…
Indications
Worked on PROGLYCEM at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.